Tumor Biology

, Volume 37, Issue 7, pp 8599–8607 | Cite as

MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer

  • Min Zheng
  • Zhihao Wu
  • Anqi Wu
  • Zhenyu Huang
  • Na He
  • Xiaohong XieEmail author
Original Article


Researches indicate that the dysregulation of microRNA (miRNA) is involved in tumorigenesis. Among such dysregulated miRNAs in cancer, miR-145 is reported to be downregulated in multiple cancers. In this study, we demonstrated the downregulation of miR-145 in triple-negative breast cancer (TNBC) tissues and TNBC cell lines by quantitative reverse-transcription polymerase chain reaction (RT-PCR) analysis. Furthermore, we found that the tumor necrosis factor-alpha (TNF-α)-induced apoptosis was expanded by the transfection of miR-145 in MDA-MB-231 which belongs to the TNBC cell lines. We then indicated that the mechanism by which miR-145 promotes the TNF-α-induced apoptosis is dependent on the formation of RIP1-FADD-caspase-8 complex. The cellular inhibitor of apoptosis (cIAP1), which is the inhibitor of apoptosis protein, was found to be a target of miR-145 in MDA-MB-231 cells. As a result of cIAP1 overexpression, the promotion of miR-145 on TNF-α-induced apoptosis was inhibited in MDA-MB-231 cells. Therefore, our results indicate that miR-145 acts as a tumor suppressor in TNBC, suggesting that the miR-145-cIAP1 axis might be a potential therapeutic target for TNBC.


TNBC miR-145 cIAP1 TNF-α RIP1-FADD-caspase-8 



This study is supported by the Central Laboratory of The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University and the School of Laboratory Medicine and Life Science affiliated to Wenzhou Medical University.

Compliance with ethical standards

All samples were collected with patients’ informed consent, and this project was approved by the Ethics Committee of The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University.

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol. 2012;4:195–210.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMedGoogle Scholar
  4. 4.
    Crown J, O’Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. 2012;23:vi56–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question. Cell Mol Life Sci. 2010;67:1567–79.CrossRefPubMedGoogle Scholar
  6. 6.
    Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol. 2007;17:418–24.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ. 2007;14:400–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Wu P, Shi KJ, An JJ, Ci YL, Li F, Hui KY, et al. The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis. 2014;5, e1085.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mahul-Mellier AL, Pazarentzos E, Datler C, Iwasawa R, AbuAli G, Lin B, et al. De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. Cell Death Differ. 2012;19:891–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.CrossRefPubMedGoogle Scholar
  12. 12.
    Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704–14.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590–610.CrossRefPubMedGoogle Scholar
  14. 14.
    Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2015.Google Scholar
  15. 15.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Chang CF, Ke CY, Wu YC, Chuang TH. Structure-activity relationship of synthetic 2-phenylnaphthalenes with hydroxyl groups that inhibit proliferation and induce apoptosis of MCF-7 cancer cells. PLoS One. 2015;10, e0141184.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Abhari BA, Cristofanon S, Kappler R, von Schweinitz D, Humphreys R, Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene. 2013;32:3263–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Roberge S, Roussel J, Andersson DC, Meli AC, Vidal B, Blandel F, et al. TNF-α-mediated caspase-8 activation induces ROS production and TRPM2 activation in adult ventricular myocytes. Cardiovasc Res. 2014;103:90–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Leibowitz B, Qiu W, Buchanan ME, Zou F, Vernon P, Moyer MP, et al. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111:16520–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30:689–700.CrossRefPubMedGoogle Scholar
  22. 22.
    Jiang C, Long J, Liu B, Xie X, Kuang M. Mcl-1 is a novel target of miR-26b that is associated with the apoptosis induced by TRAIL in HCC cells. Biomed Res Int. 2015;2015:572738.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013;8:e77623.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zheng Y, Lv X, Wang X, Wang B, Shao X, Huang Y, Shi L, Chen Z, Huang J, Huang P. miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep. 2015.Google Scholar
  25. 25.
    Shen H, Shen J, Wang L, Shi Z, Wang M, Jiang BH, et al. Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother. 2015;69:301–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Chang S, Gao L, Yang Y, Tong D, Guo B, Liu L, et al. miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells. Oncotarget. 2015;6:7675–785.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Liu RL, Dong Y, Deng YZ, Wang WJ, Li WD. Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumour Biol. 2015;36:5011–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Larne O, Hagman Z, Lilja H, Bjartell A, Edsjö A, Ceder Y. miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis. 2015;36:858–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Ma Y, Zhao S, Shen S, Fang S, Ye Z, Shi Z, et al. A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis. Sci Rep. 2015;5:13595.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NFkB activation, and TNFα-dependent apoptosis. Cell. 2007;131:669–81.CrossRefPubMedGoogle Scholar
  31. 31.
    McEleny K, Coffey R, Morrissey C, Williamson K, Zangemeister-Wittke U, Fitzpatrick JM, et al. An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate. 2004;59:419–25.CrossRefPubMedGoogle Scholar
  32. 32.
    Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, et al. Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Res. 2009;19:1079–89.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Min Zheng
    • 1
  • Zhihao Wu
    • 1
  • Anqi Wu
    • 2
  • Zhenyu Huang
    • 2
  • Na He
    • 2
  • Xiaohong Xie
    • 3
    Email author
  1. 1.Department of Breast SurgeryThe Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical UniversityWenzhouChina
  2. 2.School of Laboratory Medicine and Life ScienceWenzhou Medical UniversityWenzhouChina
  3. 3.Department of Breast SurgeryZhejiang Provincial Hospital of Traditional Chinese MedicineHangzhou CityChina

Personalised recommendations